Novartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer

NEXT STORY
The U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments
PREV STORY
Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Pivotal Preclinical Oncology Platform Expands to Include New Patient-Derived Organoid Models

author_avatar
NASDAQ Market News

Oncology Pharma Signed a Letter of Intent with Kalos Therapeutics for an Exclusive World-Wide Licence and Co-Devlopent of Its Broad-Spectrum Anti-Cancer Drug, KTH 222

author_avatar
NASDAQ Market News

Neovacs obtains FDA approval to extend its Phase IIb clinical trial in Lupus to United States

PARIS and BOSTON, April 28, 2016 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV) a leader ...

author_avatar
NASDAQ Market News